XK469, a novel antitumor agent, inhibits signaling by the MEK/MAPK signaling pathway

Cancer Chemotherapy and Pharmacology

Volumn 49, Issue 4, 2002, Pages 281-286

  Lin, Hong ^a,b   Subramanian, Balanehru ^a,b   Nakeff, Alex ^a,b   Chen, Ben D ^a,b  

^a KARMANOS CANCER INSTITUTE   (United States)

^b HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

Antiproliferation; MAPK; MEK; XK469

Indexed keywords

AMSACRINE; ANTINEOPLASTIC AGENT; CYCLIN A; CYCLIN B1; DOXORUBICIN; ENZYME ANTIBODY; MITOGEN ACTIVATED PROTEIN KINASE; MW 326; NSC 697887; QUINOXALINE PHENYLOXYPROPIONIC ACID DERIVATIVE; UNCLASSIFIED DRUG; VINBLASTINE; XK 469;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE G2 PHASE; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MITOSIS INHIBITION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL SURVIVAL; CYCLIN B; ENZYME INHIBITORS; G2 PHASE; HUMANS; MAP KINASE KINASE KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASES; MITOSIS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; QUINOXALINES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036201940     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-002-0425-7     Document Type: Article

References (23)

1. Preclinical antitumor activity of XK469 (NSC 656889)
2. Preclinical antitumor efficacy of analogs of XK469: Sodium-(2-[4-(7- chloro22-quinoxalinyloxy) phenoxy]propionate
3. XK469, a selective topoisomerase IIbeta poison
4. Pro-apoptotic nteractions between XK469 and the peripheral benzodiazepine receptor
5. Mechanism of antitumor action of a novel quinoxaline, XK469
6. Mitotic arrest induced by XK469, a novel antitumor agent, is correlated with the inhibition of cyclin B1 ubiquiti-nation
7. Meaningful relationships: The regulation of the Ras/Raf/MEK/ERK pathway by protein interactions
8. Mitogen-activated protein kinase pathways
9. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors
10. Constitutive activation of extracellular signal-regulated kinase in human acute leukemias: Combined role of activation of MEK, hyperexpression of extracellular signal-regulated kinase, and downregulation of a phosphatase, PAC1
11. Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling
12. 2/M transition induced by nocodazole
13. Establishment and characterization of a human histiocytic lymphoma cell line (U-937)
14. Human THP-1 monocytic leukemic cells induced to undergo monocytic differentiation by bryostatin 1 are refractory to proteasome inhibitor-induced apoptosis
15. Resistance of bone marrow-derived macrophages to apoptosis is associated with the expression of X-linked inhibitor of apoptosis protein (XIAP) in primary cultures of bone marrow cells
16. Cdc2 regulatory factors
17. The cyclin-dependent protein kinases and the control of cell division
18. Regulation of the cyclin B degradation system by an inhibitor of mitotic proteolysis
19. Mechanisms and regulation of ubiquitin-mediated cyclin degradation
20. The ubiquitin-mediated proteolytic pathway as a therapeutic area
21. Cyclin-dependent kinase inhibitors: Useful targets in cell cycle regulation
22. DNA damage induces p21 protein expression by inhibiting ubiquitination in ML-1 cells
23. Effect of ionizing radiation on wild-type and mutant mouse leukemia L1210 cells